Frankfurt, 08.04.2005
Dr. Martin Zügel was named CEO for Merz Pharmaceuticals and the dental business of the Merz Group, effective April 1, 2005. He will specifically focus on corporate strategy, new business and expansion of the company internationally, to ensure a continued organic company growth.
Dr. Zügel is a molecular biologist and holds a Ph.D. in medicine from the University of Tübingen in Germany. In his new role, Dr. Zügel will bring to Merz his leadership and international expertise he developed during his time at Boehringer Mannheim/Hoffmann La Roche AG (Mannheim/Grenzach, Germany) and B. Braun Melsungen AG (Melsungen, Germany). Most recently, Dr. Zügel was a member of the Managing board at B. Braun and responsible for the Hospital Care division and the Asia Pacific region.
Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Merz is a leader in the field of Alzheimer research and developed the first drug for the treatment of moderate to severe Alzheimer's. Other franchise covered by Merz are hepatology/metabolic diseases and dermatology.
![back to top [link]](skin_img/skin_contentSiteInfo-backToTop-arrow.gif)
Last update: 14 Mai 2007, 04:26
produced by GPM mbH
URL: http://www.merz.com/press/press-releases/company/2005/04/08/01/
Last update: 14.05.2007, 16:26 Uhr
© 2008 Merz. All rights reserved.